EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathy

Emma van den Berg iD, Iris Kersten iD, Gunnar Brinkmalm iD, Kjell Johansson iD, Anna M de Kort iD, Catharina J M Klijn iD, Floris H B M Schreuder iD, Johan Gobom iD, Erik Stoops iD, Erik Portelius iD, Eleni Gkanatsiou iD, Henrik Zetterberg iD und 3 weitere

Journal of Neurochemistry · 2024-07 · 168 (7) · 1254-1264

DOI: 10.1111/jnc.16074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurochemistry, online erschienen am 16.02.2024. Verfasst von Emma van den Berg und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Cerebral Amyloid Angiopathy, Amyloid beta-Peptides, Biomarkers, Alzheimer Disease. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, ZonMw, The Galen and Hilary Weston Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brain amyloid‐β (Aβ) deposits are key pathological hallmarks of both cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD). Microvascular deposits in CAA mainly consist of the Aβ 40 peptide, whereas Aβ 42 is the predominant variant in parenchymal plaques in AD. The relevance in pathogenesis and diagnostic accuracy of various other Aβ isoforms in CAA remain understudied. We aimed to investigate the biomarker potential of various Aβ isoforms in cerebrospinal fluid (CSF) to differentiate CAA from AD pathology. We included 25 patients with probable CAA, 50 subjects with a CSF profile indicative of AD pathology (AD‐like), and 23 age‐ and sex‐matched controls. CSF levels of Aβ 1‐34 , Aβ 1‐37 , Aβ 1‐38 , Aβ 1‐39 , Aβ 1‐40 , and Aβ 1‐42 were quantified by liquid chromatography mass spectrometry. Lower CSF levels of all six Aβ peptides were observed in CAA patients compared with controls ( p = 0.0005–0.03). Except for Aβ 1‐42 ( p = 1.0), all peptides were decreased in CAA compared with AD‐like subjects ( p = 0.007–0.03). Besides Aβ 1‐42 , none of the Aβ peptides were decreased in AD‐like subjects compared with controls. All Aβ peptides combined differentiated CAA from AD‐like subjects better (area under the curve [AUC] 0.84) than individual peptide levels (AUC 0.51–0.75). Without Aβ 1‐42 in the model (since decreased Aβ 1‐42 served as AD‐like selection criterion), the AUC was 0.78 for distinguishing CAA from AD‐like subjects. CAA patients and AD‐like subjects showed distinct disease‐specific CSF Aβ profiles. Peptides shorter than Aβ 1‐42 were decreased in CAA patients, but not AD‐like subjects, which could suggest different pathological mechanisms between vascular and parenchymal Aβ accumulation. This study supports the potential use of this panel of CSF Aβ peptides to indicate presence of CAA pathology with high accuracy. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebral Amyloid AngiopathyAmyloid beta-PeptidesBiomarkersAlzheimer DiseaseHumansFemaleMaleAgedMiddle AgedPeptide FragmentsAged, 80 and over

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid‐βbiomarkerscerebral amyloid angiopathycerebrospinal fluidmass spectrometry

Substanzen

Amyloid beta-PeptidesBiomarkersPeptide Fragments

Autor:innen und Institutionen

  • Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • ADx NeuroSciences, Ghent, Belgium.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • UK Dementia Research Institute at UCL, London, UK.

ORCID-Profile: Emma van den Berg, Iris Kersten, Gunnar Brinkmalm, Kjell Johansson, Anna M de Kort, Catharina J M Klijn, Floris H B M Schreuder, Johan Gobom, Erik Stoops, Erik Portelius, Eleni Gkanatsiou, Henrik Zetterberg, Kaj Blennow, H Bea Kuiperij, Marcel M Verbeek

Förderung

  • NINDS NIH HHS
  • ZonMw
  • The Galen and Hilary Weston Foundation
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

van den Berg, E., Kersten, I., Brinkmalm, G., Johansson, K., de Kort, A. M., Klijn, C. J. M., Schreuder, F. H. B. M., Gobom, J., Stoops, E., Portelius, E., Gkanatsiou, E., Zetterberg, H., Blennow, K., Kuiperij, H. B., & Verbeek, M. M. (2024). Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathy. Journal of Neurochemistry, 168(7), 1254-1264. https://doi.org/10.1111/jnc.16074

Vancouver

van den Berg E, Kersten I, Brinkmalm G, Johansson K, de Kort AM, Klijn CJM, et al. Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathy. Journal of Neurochemistry. 2024;168(7):1254-1264. doi:10.1111/jnc.16074

BibTeX
@article{vandenBerg2024,
  author = {van den Berg, Emma and Kersten, Iris and Brinkmalm, Gunnar and Johansson, Kjell and de Kort, Anna M and Klijn, Catharina J M and Schreuder, Floris H B M and Gobom, Johan and Stoops, Erik and Portelius, Erik and Gkanatsiou, Eleni and Zetterberg, Henrik and Blennow, Kaj and Kuiperij, H Bea and Verbeek, Marcel M},
  title = {Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathy},
  journal = {Journal of Neurochemistry},
  year = {2024},
  volume = {168},
  number = {7},
  pages = {1254--1264},
  doi = {10.1111/jnc.16074}
}
Kostenlos starten →